PMID- 30142537
OWN - NLM
STAT- MEDLINE
DCOM- 20181224
LR  - 20181224
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 107
DP  - 2018 Nov
TI  - Orexin A may suppress inflammatory response in fibroblast-like synoviocytes.
PG  - 763-768
LID - S0753-3322(18)32741-0 [pii]
LID - 10.1016/j.biopha.2018.07.159 [doi]
AB  - Orexins are peptides found in the hypothalamus and other peripheral tissues 
      including adipose tissue, the endocrine cells of the gut, adrenal gland testis, 
      and the pancreas. They play important roles in neuro-protection by inhibiting 
      oxidative stress and inflammatory response via their type 1 and 2 receptors (OX1R 
      and OX2R). The expressions of OX1R and OX2R were detected and the physiological 
      function of orexin A in fibroblast-like synoviocytes (FLSs) was investigated in 
      this study. Only OX1R was found on FLSs and the expression of OX1R was decreased 
      in fibroblast-like synoviocytes in rheumatoid arthritis (RA-FLSs) and tumor 
      necrosis factor-alpha (TNF-alpha)-treated FLSs. Orexin A exhibited an anti-inflammatory 
      effect on TNF-alpha treated FLSs. Particularly, orexin A treatment reduced the 
      secretions of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and interleukin-8 
      (IL-8) as well as the production of reactive oxygen species (ROS). Importantly, 
      we showed that orexin A ameliorated the expression of matrix metalloproteinase-3 
      (MMP-3) and matrix metalloproteinase-13 (MMP-13). Mechanistically, we found that 
      orexin A inhibited TNF-alpha-induced activation of the nuclear factor-kappaB (NF-kappaB) 
      signaling pathway. The current study provides a basis for the potential 
      application of orexin A in the clinical treatment of RA.
CI  - Copyright (c) 2018 Elsevier Masson SAS. All rights reserved.
FAU - Sun, Minghui
AU  - Sun M
AD  - Department of Joint Surgery, The Affiliated Drum Tower Hospital of Nanjing 
      University Medical School, Nanjing, 210008, China.
FAU - Wang, Weijun
AU  - Wang W
AD  - Department of Joint Surgery, The Affiliated Drum Tower Hospital of Nanjing 
      University Medical School, Nanjing, 210008, China.
FAU - Li, Qing
AU  - Li Q
AD  - Department of Clinical Medicine of Chinese and Western Medicine Integration, 
      Nanjing University of Chinese Medicine, Nanjing, 210023, China.
FAU - Yuan, Tao
AU  - Yuan T
AD  - Department of Joint Surgery, The Affiliated Drum Tower Hospital of Nanjing 
      University Medical School, Nanjing, 210008, China.
FAU - Weng, Wenjie
AU  - Weng W
AD  - Department of Joint Surgery, The Affiliated Drum Tower Hospital of Nanjing 
      University Medical School, Nanjing, 210008, China. Electronic address: 
      drwengwenjie@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20180821
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (I-kappa B Proteins)
RN  - 0 (Interleukins)
RN  - 0 (NF-kappa B)
RN  - 0 (Orexin Receptors)
RN  - 0 (Orexins)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - EC 1.13.12.- (Luciferases)
RN  - EC 3.4.24.- (MMP13 protein, human)
RN  - EC 3.4.24.- (Matrix Metalloproteinase 13)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Arthritis, Rheumatoid/pathology
MH  - Cell Nucleus/drug effects/metabolism
MH  - Fibroblasts/drug effects/metabolism/*pathology
MH  - Humans
MH  - I-kappa B Proteins/metabolism
MH  - Inflammation/metabolism/*pathology
MH  - Interleukins/metabolism
MH  - Luciferases/metabolism
MH  - Matrix Metalloproteinase 13/metabolism
MH  - Matrix Metalloproteinase 3/metabolism
MH  - NF-kappa B/metabolism
MH  - Orexin Receptors/metabolism
MH  - Orexins/*pharmacology
MH  - Phosphorylation/drug effects
MH  - Proteolysis/drug effects
MH  - Reactive Oxygen Species/metabolism
MH  - Synoviocytes/drug effects/metabolism/*pathology
MH  - Tumor Necrosis Factor-alpha
OTO - NOTNLM
OT  - Fibroblast-like synoviocytes
OT  - Orexin A
OT  - Rheumatoid arthritis
OT  - TNF-alpha
EDAT- 2018/08/25 06:00
MHDA- 2018/12/26 06:00
CRDT- 2018/08/25 06:00
PHST- 2018/04/24 00:00 [received]
PHST- 2018/07/18 00:00 [revised]
PHST- 2018/07/31 00:00 [accepted]
PHST- 2018/08/25 06:00 [pubmed]
PHST- 2018/12/26 06:00 [medline]
PHST- 2018/08/25 06:00 [entrez]
AID - S0753-3322(18)32741-0 [pii]
AID - 10.1016/j.biopha.2018.07.159 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2018 Nov;107:763-768. doi: 10.1016/j.biopha.2018.07.159. 
      Epub 2018 Aug 21.